New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

Palbace (palbociclib) capsules, for oral use

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email to discuss.

Facts of Palbace (palbociclib)

Brand Name: Palbace
Generic Name: palbociclib
Initial U.S. Approval: 2015
Manufacturer: Pfizer
Presentation: Capsule
Strength: 125mg
Pack Size:21 Capsules per bottle

South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Palbace (palbociclib)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Palbace (palbociclib) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.


Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:

Query Form


What Palbace is?

IBRANCE is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:

  • an aromatase inhibitor as initial endocrine based therapy in postmenopausal women; or
  • fulvestrant in women with disease progression following endocrine therapy

What palbociclib is?

Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.


Related Products